Performance of PRS based on pancreatic cancer susceptibility variants in the GWAS of breast cancer in the African diaspora
| Percentile of PRS | Cases (n = 1,657) | Controls (n = 2,029) | ORa (95% CI) |
|---|---|---|---|
| <5 | 165 | 204 | 0.99 (0.76–1.27) |
| 5–10 | 168 | 200 | 1.02 (0.79–1.32) |
| 10–20 | 155 | 214 | 0.85 (0.66–1.10) |
| 20–40 | 158 | 211 | 0.88 (0.68–1.13) |
| 40–60 | 336 | 400 | 1.00 (ref) |
| 60–80 | 171 | 199 | 1.00 (0.78–1.29) |
| 80–90 | 166 | 201 | 0.98 (0.76–1.27) |
| 90–95 | 173 | 197 | 1.01 (0.78–1.30) |
| >95 | 165 | 203 | 0.97 (0.75–1.25) |
| Continuous (per SD = 0.571) | — | — | 1.01 (0.95–1.08) |
↵aORs are for different percentiles of the polygenic PRS relative to the middle quintile (40%–60%) and were adjusted for age, study site, and the first four eigenvectors from principal components analysis.